Treatment of central nervous system manifestations in mitochondrial disorders

European Journal of Neurology

Volumn 18, Issue 1, 2011, Pages 28-38

  Finsterer, J ^a  

^a DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

Brain; Cerebrum; Encephalomyopathy; Mitochondrial cytopathy; Mitochondriopathy; Multi system disease; Oxidative phosphorylation; Respiratory chain; Spinal cord

Indexed keywords

ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIOXIDANT; ARGININE; ASCORBIC ACID; ASPARTIC ACID; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CARNITINE; CREATINE; DICHLOROACETIC ACID; FOLIC ACID; GLUTATHIONE; HALOPERIDOL; IDEBENONE; LACTIC ACID; NEUROLEPTIC AGENT; NOOTROPIC AGENT; NORPHENAZONE; OXCARBAZEPINE; PHENYTOIN; PYRIDOXINE; RIBOFLAVIN; STEROID; SUCCINIC ACID; THIAMINE; UBIQUINONE; UNINDEXED DRUG; VITAMIN K GROUP;

ARTIFICIAL VENTILATION; ATAXIA; ATHETOSIS; BRAIN DEPTH STIMULATION; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CHOREA; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DEMENTIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSARTHRIA; DYSPHAGIA; DYSPNEA; DYSTONIA; ELECTRON TRANSPORT; GENE DELETION; GENE THERAPY; GENETIC CODE; GERM LINE GENE THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOPITUITARISM; KETOGENIC DIET; LEBER HEREDITARY OPTIC NEUROPATHY; MEGALOBLASTIC ANEMIA; MELAS SYNDROME; MENTAL DEFICIENCY; MERRF SYNDROME; MIGRAINE; MOOD DISORDER; MUSCLE HYPOTONIA; NARP SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; PARKINSONISM; PHYSIOTHERAPY; POINT MUTATION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PSYCHOSIS; RESPIRATORY CHAIN; RESTLESS LEGS SYNDROME; REVIEW; SEIZURE; SLEEP APNEA SYNDROME; SPASTICITY; STEM CELL TRANSPLANTATION; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREMOR; VASCULAR DISEASE;

BRAIN; HUMANS; MITOCHONDRIAL DISEASES; NERVOUS SYSTEM DISEASES;

EID: 78650142198     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03086.x     Document Type: Review

References (88)

1. DiMauro S, Schon EA. Mitochondrial disorders in the nervous system. Annu Rev Neurosci 2008; 31: 91-123.
2. Finsterer J, Jarius C, Eichberger H, et al. Phenotype variability in 130 adult patients with respiratory chain disorder. J Inherit Metab Dis 2001; 24: 560-576.
3. Horvath R, Gorman G, Chinnery PF. How can we treat mitochondrial encephalomyopathies? Approaches to therapy. Neurotherapeutics 2008; 5: 558-568.
4. Iizuka T, Goto Y, Miyakawa S, et al. Progressive carotid artery stenosis with a novel tRNA phenylalanine mitochondrial DNA mutation. J Neurol Sci 2009; 278: 35-40.
5. Finsterer J, Stöllberger C. Primary myopathies and the heart. Scand Cardiovasc J 2008; 42: 9-24.
6. Finsterer J. Central nervous system manifestations of mitochondrial disorders. Acta Neurol Scand 2006; 114: 217-238.
7. Peng NJ, Liu RS, Li JY, et al. Increased cerebral blood flow in MELAS shown by Tc-99m HMPAO brain SPECT. Neuroradiology 2000; 42: 26-29.
8. Shah NS, Mitchell WG, Boles RG. Mitochondrial disorders: a potentially under-recognized etiology of infantile spasms. J Child Neurol 2002; 17: 369-372.
9. Finsterer J, Harbo HF, Baets J, et al. EFNS guidelines on the molecular diagnosis of mitochondrial disorders. Eur J Neurol 2009; 16: 1255-1264.
10. Edvardson S, Shaag A, Kolesnikova O, et al. Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. Am J Hum Genet 2007; 81: 857-862.
11. Aniello MS, Martino D, Petruzzella V, et al. Bilateral striatal necrosis, dystonia and multiple mitochondrial DNA deletions: case study and effect of deep brain stimulation. Mov Disord 2008; 23: 114-118.
12. Finsterer J Treatment of mitochondrial disorders. Eur J Paediatr Neurol 2010; 14: 29-44.
13. Komaki H, Nishigaki Y, Fuku N, et al. Pyruvate therapy for Leigh syndrome due to cytochrome c oxidase deficiency. Biochim Biophys Acta 2010; 1800: 313-315.
14. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997; 37: 212-218.
15. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35: 235-242.
16. Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990; 100: 70-78.
17. Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets 2010; 11: 111-121.
18. Bugiani M, Lamantea E, Invernizzi F, et al. Effects of riboflavin in children with complex II deficiency. Brain Dev 2006; 28: 576-581.
19. Zaffanello M, Beghini R, Zamboni G, Fanos V. A sporadic case of cystinuria, respiratory chain and growth hormone deficiencies. Pediatr Nephrol 2003; 18: 846-847.
20. Oguro H, Iijima K, Takahashi K, et al. Successful treatment with succinate in a patient with MELAS. Intern Med 2004; 43: 427-431.
21. DiMauro S, Hirano M, Schon EA. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 2006; 34: 265-283.
22. Mori M, Yamagata T, Goto T, Saito S, Momoi MY. Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. Brain Dev 2004; 26: 453-458.
23. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006; 66: 324-330.
24. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997; 20: 1502-1509.
25. Klopstock T, Querner V, Schmidt F, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000; 55: 1748-1751.
26. Kornblum C, Schröder R, Müller K, et al. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. Eur J Neurol 2005; 12: 300-309.
27. Toth G, Morava E, Bene J, et al. Carnitine-responsive carnitine insufficiency in a case of mtDNA 8993T>C mutation associated Leigh syndrome. J Inherit Metab Dis 2001; 24: 421-422.
28. Scharfe C, Hauschild M, Klopstock T, et al. A novel mutation in the thiamin responsive in a patient with deficiency of respiratory chain complex I. J Med Genet 2000; 37: 669-673.
29. Koga Y, Ishibashi M, Ueki I, et al. Effects of L-arginine on the acute phase of strokes in three patients with MELAS. Neurology 2002; 58: 827-828.
30. Tinsa F, Ben Amor S, Kaabachi N, Ben Lasouad M, Boussetta K, Bousnina S. Unusual case of thiamine responsive megaloblastic anemia. Tunis Med 2009; 87: 159-163.
31. Sato Y, Nakagawa M, Higuchi I, Osame M, Naito E, Oizumi K. Mitochondrial myopathy and familial thiamin deficiency. Muscle Nerve 2000; 23: 1069-1075.
32. Ramaekers VT, Weis J, Sequeira JM, Quadros EV, Blau N. Mitochondrial complex I encephalomyopathy and cerebral 5-methyltetrahydrofolate deficiency. Neuropediatrics 2007; 38: 184-187.
33. Finsterer J, Segall L Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 2010; 33: 138-151.
34. Tarnopolsky MA. Mitochondrial DNA shifting in older adults following resistance exercise training. Appl Physiol Nutr Metab 2009; 34: 348-354.
35. Murphy JL, Blakely EL, Schaefer AM, et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 2008; 131: 2832-2840.
36. Taivassalo T, Haller RG. Exercise and training in mitochondrial myopathies. Med Sci Sports Exerc 2005; 37: 2094-2101.
37. Joshi CN, Greenberg CR, Mhanni AA, Salman MS. Ketogenic diet in Alpers-Huttenlocher syndrome. Pediatr Neurol 2009; 40: 314-316.
38. Kang HC, Lee YM, Kim HD, Lee JS, Slama A. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007; 48: 82-88.
39. Wortmann SB, Zweers-van Essen H, Rodenburg RJ, et al. Mitochondrial energy production correlates with the age-related BMI. Pediatr Res 2009; 65: 103-108.
40. Bieleń P, Sliwiński P, Kamiński D, Zieliński J. Respiratory failure in mitochondrial myopathy treated with noninvasive mechanical ventilation. Pneumonol Alergol Pol 1998; 66: 555-559.
41. van Kesteren RG, Kampelmacher MJ. Mechanical ventilation in neuromuscular diseases: do not start too early, but certainly not too late. Ned Tijdschr Geneeskd 2000; 144: 1249-1252.
42. Schweitzer C, Camoin-Schweitzer MC, Beltramo F, Polu E, Marchal F, Monin P. Domiciliary assisted ventilation in children. Rev Pneumol Clin 2002; 58: 139-144.
43. Kovacs N, Pal E, Balas I, Janszky J, Nagy F, Merkli H. Neurosurgical treatment of tremor in mitochondrial encephalopathy. Mov Disord 2006; 21: 2227-2230.
44. Díaz-Lobato S, Gómez Mendieta MA, Moreno García MS, Mayoralas-Alises S, Arpa Gutierrez FJ. Two full-term pregnancies in a patient with mitochondrial myopathy and chronic ventilatory insufficiency. Respiration 2005; 72: 654-656.
45. O'Donnell DM. Pulmonary complications in neuromuscular disease. Adolesc Med 2000; 11: 633-645.
46. Ortí-Pareja M, Jiménez-Jiménez FJ, Barcenilla B, Montero E, Marcos J, García-Albea E. Respiratory insufficiency as the first sign of mitochondrial disorders. Rev Neurol 1999; 29: 735-736.
47. Tsujita Y, Kunitomo T, Fujii M, et al. A surviving case of mitochondrial cardiomyopathy diagnosed from the symptoms of multiple organ dysfunction syndrome. Int J Cardiol 2008; 128: e43-e45.
48. Lara MC, Weiss B, Illa I, et al. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 2006; 67: 1461-1463.
49. Lee YM, Kang HC, Lee JS, et al. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia 2008; 49: 685-690.
50. Santos NA, Medina WS, Martins NM, Mingatto FE, Curti C, Santos AC. Aromatic antiepileptic drugs and mitochondrial toxicity: effects on mitochondria isolated from rat liver. Toxicol In Vitro 2008; 22: 1143-1152.
51. Chiyonobu T, Noda R, Yoshida M, et al. Intestinal pseudo-obstruction in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) associated with phenytoin therapy. Brain Dev 2008; 30: 430-433.
52. Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007; 22: 105-109.
53. Wolf NI, Rahman S, Schmitt B, et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009; 50: 1596-1607.
54. Uusimaa J, Finnilä S, Vainionpää L, et al. A mutation in mitochondrial DNA-encoded cytochrome c oxidase II gene in a child with Alpers-Huttenlocher-like disease. Pediatrics 2003; 111: e262-e268.
55. McFarland R, Hudson G, Taylor RW, et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Arch Dis Child 2008; 93: 151-153.
56. Costello DJ, Sims KB. Efficacy of lamotrigine in disabling myoclonus in a patient with an mtDNA A3243G mutation. Neurology 2009; 72: 1279-1280.
57. Gibbs JE, Walker MC, Cock HR. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006; 47: 469-478.
58. Mancuso M, Galli R, Pizzanelli C, Filosto M, Siciliano G, Murri L. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006; 243: 97-99.
59. Finsterer J, Stöllberger C Psychomotor improvement from dog-ownership in MELAS syndrome. Gazz Med Ital 2009; 168: 269-272.
60. Morota S, Månsson R, Hansson MJ, et al. Evaluation of putative inhibitors of mitochondrial permeability transition for brain disorders--specificity vs. toxicity. Exp Neurol 2009; 218: 353-362.
61. Yagi K. Overview of Japanese experience-controlled and uncontrolled trials. Seizure 2004; 13(Suppl. 1): S11-S15.
62. Desguerre I, Pinton F, Nabbout R, et al. Infantile spasms with basal ganglia MRI hypersignal may reveal mitochondrial disorder due to T8993G MT DNA mutation. Neuropediatrics 2003; 34: 265-269.
63. Nakagaki H, Furuya J, Santa Y, Nagano S, Araki E, Yamada T. A case of MELAS presenting juvenile-onset hyperglycemic chorea-ballism. Rinsho Shinkeigaku 2005; 45: 502-505.
64. Balestri P, Grosso S. Endocrine disorders in two sisters affected by MELAS syndrome. J Child Neurol 2000; 15: 755-758.
65. De Sanctis V, Calzolari F, Piazzi A, Berio A. Kearns-Sayre syndrome associated with growth hormone deficiency. Pediatr Med Chir 2003; 25: 447-451.
66. Matsuzaki M, Izumi T, Shishikura K, Suzuki H, Hirayama Y. Hypothalamic growth hormone deficiency and supplementary GH therapy in two patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes. Neuropediatrics 2002; 33: 271-273.
67. Romano S, Samara D, Crosnier H, et al. Variable outcome of growth hormone administration in respiratory chain deficiency. Mol Genet Metab 2008; 93: 195-199.
68. Boles RG, Roe T, Senadheera D, Mahnovski V, Wong LJ. Mitochondrial DNA deletion with Kearns Sayre syndrome in a child with Addison disease. Eur J Pediatr 1998; 157: 643-647.
69. Finsterer J. Cognitive decline as a manifestation of mitochondrial disorders (mitochondrial dementia). J Neurol Sci 2008; 272: 20-33.
70. Koene S, Kozicz TL, Rodenburg RJ, et al. Major depression in adolescent children consecutively diagnosed with mitochondrial disorder. J Affect Disord 2009; 114: 327-332.
71. Turunen JA, Rehnström K, Kilpinen H, Kuokkanen M, Kempas E, Ylisaukko-Oja T. Mitochondrial aspartate/glutamate carrier SLC25A12 gene is associated with autism. Autism Res 2008; 1: 189-192.
72. Finsterer J Management of mitochondrial stroke-like episodes. Eur J Neurol 2009; 16: 1178-1184.
73. Koga Y. L-arginine therapy on MELAS. Rinsho Shinkeigaku 2008; 48: 1010-1012.
74. Kubota M, Sakakihara Y, Mori M, Yamagata T, Momoi-Yoshida M. Beneficial effect of L-arginine for stroke-like-episode in MELAS. Brain Dev 2004; 26: 481-483.
75. Moutaouakil F, El Otmani H, Fadel H, Sefrioui F, Slassi I. L-arginine efficiency in MELAS-syndrome. A case report. Rev Neurol (Paris) 2009; 165: 482-485.
76. Toribe Y, Tominaga K, Ogawa K, Suzuki Y. Usefulness of L-arginine infusion for status epilepticus in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like-episodes. No To Hattatsu 2007; 39: 38-43.
77. Nakano K, Tarashima M, Tachikawa E, et al. Platelet mitochondrial evaluation during cytochrome c and dichloroacetate treatments of MELAS. Mitochondrion 2005; 5: 426-433.
78. Maeda K, Tatsumi M, Tahara M, Murata Y, Kawai H, Yasuda H. A case of stroke-like-episode of MELAS of which progressive spread would be prevented by edaravone. Rinsho Shinkeigaku 2005; 45: 416-421.
79. Abe K, Inui T, Hirono N, Mezaki T, Kobayashi Y, Kameyama M. Fluctuating MR images with mitochondrial encephalopathy, lactic acidosis, stroke-like-syndrome (MELAS). Neuroradiology 1990; 32: 77.
80. Berbel-Garcia A, Barbera-Farre JR, Etessam JP, et al. Coenzyme Q 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol 2004; 27: 187-191.
81. Napolitano A, Salvetti S, Vista M, Lombardi V, Siciliano G, Giraldi C. Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci 2000; 21(Suppl. 5): S981-S982.
82. Di Prospero NA, Sumner CJ, Penzak SR, Ravina B, Fischbeck KH, Taylor JP. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 2007; 64: 803-808.
83. Barisic N, Bernert G, Ipsiroglu O, et al. Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. Neuropediatrics 2002; 33: 157-161.
84. Rossi FH, Okun M, Yachnis A, Quisling R, Triggs WJ. Corticosteroid treatment of mitochondrial encephalomyopathies. Neurologist 2002; 8: 313-315.
85. De Stefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995; 45: 1193-1198.
86. Liet JM, Pelletier V, Robinson BH, et al. The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. J Pediatr 2003; 142: 62-66.
87. Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005; 64: 710-712.
88. Iizuka T, Sakai F, Kan S, Suzuki N. Slowly progressive spread of the stroke-like lesions in MELAS. Neurology 2003; 61: 1238-1244.